Literature DB >> 19574645

Production, purification, crystallization and preliminary X-ray diffraction analysis of the HIV-2-neutralizing V3 loop-specific Fab fragment 7C8.

Hannes Uchtenhagen1, Samer Sourial, Rosmarie Friemann, Mariethe Ehnlund, Anna-Lena Spetz, Robert A Harris, Chaithanya Madhurantakam, Adnane Achour.   

Abstract

7C8 is a mouse monoclonal antibody that is specific for the third hypervariable loop (V3 loop) of the human immunodeficiency virus type 2 (HIV-2) associated protein gp125. Fab fragments of 7C8 effectively neutralize HIV-2. 7C8 was expressed and purified from a hybridoma cell line in order to establish the molecular basis underlying the specificity of the 7C8 antibody for the V3 loop as well as the specific role of the elongated third complementarity-determining region of the heavy chain (CDRH3). The antibody was digested with papain and Fab fragments were purified using size-exclusion chromatography. Hanging-drop vapour-diffusion crystallization techniques were employed and the protein was crystallized in 50 mM ammonium sulfate, 100 mM Tris-HCl pH 8.5, 25%(w/v) PEG 8000 and 2.5%(w/v) PEG 400 at 275 K. The analysed crystals belonged to the rhombohedral space group P3(2)21, with unit-cell parameters a = b = 100.1, c = 196.8 A, and diffracted to 2.7 A resolution.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19574645      PMCID: PMC2705640          DOI: 10.1107/S1744309109020685

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  24 in total

1.  Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs.

Authors:  R Stanfield; E Cabezas; A Satterthwait; E Stura; A Profy; I Wilson
Journal:  Structure       Date:  1999-02-15       Impact factor: 5.006

2.  Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen.

Authors:  Abigail V J Collis; Adam P Brouwer; Andrew C R Martin
Journal:  J Mol Biol       Date:  2003-01-10       Impact factor: 5.469

3.  Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D.

Authors:  Robyn L Stanfield; Miroslaw K Gorny; Constance Williams; Susan Zolla-Pazner; Ian A Wilson
Journal:  Structure       Date:  2004-02       Impact factor: 5.006

4.  Deletion of the V1/V2 region does not increase the accessibility of the V3 region of recombinant gp125.

Authors:  Samer Sourial; Charlotta Nilsson; Anette Wärnmark; Adnane Achour; Robert A Harris
Journal:  Curr HIV Res       Date:  2006-04       Impact factor: 1.581

5.  Solvent content of protein crystals.

Authors:  B W Matthews
Journal:  J Mol Biol       Date:  1968-04-28       Impact factor: 5.469

Review 6.  Antibody vs. HIV in a clash of evolutionary titans.

Authors:  Dennis R Burton; Robyn L Stanfield; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-11       Impact factor: 11.205

7.  Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop.

Authors:  Robyn L Stanfield; Jayant B Ghiara; Erica Ollmann Saphire; Albert T Profy; Ian A Wilson
Journal:  Virology       Date:  2003-10-10       Impact factor: 3.616

8.  Preferred CDRH3 lengths for antibodies with defined specificities.

Authors:  G Johnson; T T Wu
Journal:  Int Immunol       Date:  1998-12       Impact factor: 4.823

9.  Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2.

Authors:  E Björling; F Chiodi; G Utter; E Norrby
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

10.  Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1.

Authors:  J York; K E Follis; M Trahey; P N Nyambi; S Zolla-Pazner; J H Nunberg
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

View more
  1 in total

1.  Crystal structure of the HIV-2 neutralizing Fab fragment 7C8 with high specificity to the V3 region of gp125.

Authors:  Hannes Uchtenhagen; Rosmarie Friemann; Grzegorz Raszewski; Anna-Lena Spetz; Lennart Nilsson; Adnane Achour
Journal:  PLoS One       Date:  2011-04-26       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.